Balanced news tone
News Sentiment
GILD sentiment intelligence
Gilead Sciences, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
87/100 classification confidence.
directly relevant articles
high-authority source matches
+0.6% over one week, +6.2% over four weeks, trend inactive, and materially above fair value.
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 22:08
- Source
- Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 21:35
- Source
- GuruFocus
Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 20:55
- Source
- Stock Titan
Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:13
- Source
- Stock Titan
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 13:10
- Source
- 24/7 Wall St.
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 10:28
- Source
- StockStory
Gilead Sciences, Inc. (GILD) Stock Analysis: Promising 21.93% Upside Amid Strong Buy Ratings
- Tone
- Positive 95/100
- Event
- Market update
- Published
- 13 Jul 2026 09:12
- Source
- DirectorsTalk Interviews
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jul 2026 22:00
- Source
- Market source
Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 07:00
- Source
- simplywall.st
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000 Growth Benchmark
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 01:18
- Source
- marketscreener.com
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Jun 2026 07:00
- Source
- Market source
Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Quiver Quantitative
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Market source
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- Market source
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 23 May 2026 07:00
- Source
- Market source
Gilead Sciences Just Told Investors What to Watch Before December 23. Here’s What the Data Says About GILD Stock.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 07:00
- Source
- TIKR.com
Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q1 Adjusted EPS $2.03 per Share
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- marketscreener.com
Gilead Sciences CEO Daniel O’Day sells over $1.29m in stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- Investing.com
Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity?
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 28 Apr 2026 07:00
- Source
- CoinCentral
Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Apr 2026 07:00
- Source
- Market source
Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- marketscreener.com
Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- TIKR.com
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 17 Apr 2026 07:00
- Source
- Business Wire
Gilead extends Arcellx tender offer again (GILD:NASDAQ)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- Seeking Alpha
Gilead extends Arcellx tender offer to April 27
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- Investing.com
Coronavirus Treatment: Gilead's Remdesivir Clinical Testing, Timeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Oct 2020 07:00
- Source
- Business Insider
Gilead Sciences, Inc.: Target Price Consensus and Analysts Recommendations | GILD | US3755581036
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 19 Aug 2020 19:34
- Source
- marketscreener.com